Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Adelaide Update

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Dec 21, 2021 5:16pm

180 Views

Post# 34252396

RE:RE:Adelaide Update

Based on previous guidance I believe it's about June 2022 before the expansion will be complete. Obviously it won't be an on/off situation so should start seeing increased production from current slightly before that. This aligns with top line forecast for Q4 2022 to be in the 17-18M range. Run that out into FY2023 and we could be seeing top line number something in the 80-100M range. All this with a free Kinlytic option (currently but I doubt for much longer) and you've got an insanely cheap current valuation.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec